FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3047316303> ?p ?o ?g. }

• W3047316303 endingPage "4178" @default.
• W3047316303 startingPage "4178" @default.
• W3047316303 abstract "Abstract Background: There are several ways for malignant cells to increase their number. One of them is to use immune checkpoints protecting malignant cells from immune-mediated injury. Upregulation of immune checkpoints contributes immune escape and tumor growth. Tyrosine kinase inhibitors (TKI) have improved the outcome of chronic myeloid leukemia (CML). TKI is generally known to inhibit the target BCR-ABL1 kinase in leukemic cells. However, constantly growing evidence suggests that some TKIs activate the immune system to exert the direct cytotoxic effects. In this study, we evaluated expression levels of PD-1 on T-cells in CML patients, and found the relation with ABL kinase mutation. We analyzed the relation between the quantitative levels of BCR-ABL and PD-1 expression percentages. Methods: We obtained 82 bone marrow (BM) samples from patients diagnosed as CML at Asan medical center in Korea between May 2016 and May 2017. The samples included 22 at diagnosis (20 in chronic phase; CP and 2 in blast phase; BP) and 60 at follow-up (52 in complete hematologic remission; CHR, 1 in CP, 1 in accelerated phase; AP, and 6 in BP). All patients at follow-up were treated with Imatinib, Dasatinib, Nilotinib and/or Radotinib. Normal BM samples were collected from 23 individuals with no evidence of hematologic malignancies as the controls. Expression of PD-1 on T cells was measured using flow cytometric analysis. Results: The median expression level of PD-1 on CD8+ T cells for the patients in CHR was 21.25%, which was significantly lower than those in controls, in CP and in BP (Fig. 1). At diagnosis of CML, the median expression level of PD-1 on CD8+ T cells was 34.7%. In CML patients treated with Imatinib and/or dasatinib, the expression levels of PD-1 on CD8+ T cells were lower than at diagnosis (respectively, P Conclusion: The low expression PD-1 on CD8+ T cells might play a role in maintaining CHR in CML. The high expression of PD-1 expression in CML patients with ABL kinase mutation demonstrated that TKI had the effect of lowering the expression of PD-1 on CD8+ T cells. We conclude that PD-1 on CD8+ T cells could be important to control CML, and the immune checkpoint inhibitors might be effective in CML patients, particularly those with ABL kinase mutation. Download : Download high-res image (119KB) Download : Download full-size image Disclosures Lee: Boehringer Ingelheim: Research Funding." @default.
• W3047316303 created "2020-08-10" @default.
• W3047316303 creator A5001733777 @default.
• W3047316303 creator A5033857814 @default.
• W3047316303 creator A5044342301 @default.
• W3047316303 creator A5050880690 @default.
• W3047316303 creator A5060580143 @default.
• W3047316303 creator A5069914511 @default.
• W3047316303 creator A5072574087 @default.
• W3047316303 creator A5073296574 @default.
• W3047316303 date "2017-12-07" @default.
• W3047316303 modified "2023-09-26" @default.
• W3047316303 title "Expression Levels of PD-1 on CD8+ T Cells in Chronic Myeloid Leukemia with and without BCR-ABL1 kinase Mutation" @default.
• W3047316303 doi "https://doi.org/10.1182/blood.v130.suppl_1.4178.4178" @default.
• W3047316303 hasPublicationYear "2017" @default.
• W3047316303 type Work @default.
• W3047316303 sameAs 3047316303 @default.
• W3047316303 citedByCount "0" @default.
• W3047316303 crossrefType "journal-article" @default.
• W3047316303 hasAuthorship W3047316303A5001733777 @default.
• W3047316303 hasAuthorship W3047316303A5033857814 @default.
• W3047316303 hasAuthorship W3047316303A5044342301 @default.
• W3047316303 hasAuthorship W3047316303A5050880690 @default.
• W3047316303 hasAuthorship W3047316303A5060580143 @default.
• W3047316303 hasAuthorship W3047316303A5069914511 @default.
• W3047316303 hasAuthorship W3047316303A5072574087 @default.
• W3047316303 hasAuthorship W3047316303A5073296574 @default.
• W3047316303 hasConcept C121608353 @default.
• W3047316303 hasConcept C126322002 @default.
• W3047316303 hasConcept C154317977 @default.
• W3047316303 hasConcept C167672396 @default.
• W3047316303 hasConcept C170493617 @default.
• W3047316303 hasConcept C202751555 @default.
• W3047316303 hasConcept C203014093 @default.
• W3047316303 hasConcept C2777413986 @default.
• W3047316303 hasConcept C2777583451 @default.
• W3047316303 hasConcept C2778729363 @default.
• W3047316303 hasConcept C2778820342 @default.
• W3047316303 hasConcept C2779282312 @default.
• W3047316303 hasConcept C2779536868 @default.
• W3047316303 hasConcept C2780007613 @default.
• W3047316303 hasConcept C3019892230 @default.
• W3047316303 hasConcept C42362537 @default.
• W3047316303 hasConcept C502942594 @default.
• W3047316303 hasConcept C55493867 @default.
• W3047316303 hasConcept C71924100 @default.
• W3047316303 hasConcept C86803240 @default.
• W3047316303 hasConcept C8891405 @default.
• W3047316303 hasConceptScore W3047316303C121608353 @default.
• W3047316303 hasConceptScore W3047316303C126322002 @default.
• W3047316303 hasConceptScore W3047316303C154317977 @default.
• W3047316303 hasConceptScore W3047316303C167672396 @default.
• W3047316303 hasConceptScore W3047316303C170493617 @default.
• W3047316303 hasConceptScore W3047316303C202751555 @default.
• W3047316303 hasConceptScore W3047316303C203014093 @default.
• W3047316303 hasConceptScore W3047316303C2777413986 @default.
• W3047316303 hasConceptScore W3047316303C2777583451 @default.
• W3047316303 hasConceptScore W3047316303C2778729363 @default.
• W3047316303 hasConceptScore W3047316303C2778820342 @default.
• W3047316303 hasConceptScore W3047316303C2779282312 @default.
• W3047316303 hasConceptScore W3047316303C2779536868 @default.
• W3047316303 hasConceptScore W3047316303C2780007613 @default.
• W3047316303 hasConceptScore W3047316303C3019892230 @default.
• W3047316303 hasConceptScore W3047316303C42362537 @default.
• W3047316303 hasConceptScore W3047316303C502942594 @default.
• W3047316303 hasConceptScore W3047316303C55493867 @default.
• W3047316303 hasConceptScore W3047316303C71924100 @default.
• W3047316303 hasConceptScore W3047316303C86803240 @default.
• W3047316303 hasConceptScore W3047316303C8891405 @default.
• W3047316303 hasLocation W30473163031 @default.
• W3047316303 hasOpenAccess W3047316303 @default.
• W3047316303 hasPrimaryLocation W30473163031 @default.
• W3047316303 hasRelatedWork W1589700409 @default.
• W3047316303 hasRelatedWork W1977092622 @default.
• W3047316303 hasRelatedWork W2050352247 @default.
• W3047316303 hasRelatedWork W2128913157 @default.
• W3047316303 hasRelatedWork W2531133168 @default.
• W3047316303 hasRelatedWork W2548829044 @default.
• W3047316303 hasRelatedWork W2555386364 @default.
• W3047316303 hasRelatedWork W2565972208 @default.
• W3047316303 hasRelatedWork W2583565525 @default.
• W3047316303 hasRelatedWork W2591685873 @default.
• W3047316303 hasRelatedWork W2621376045 @default.
• W3047316303 hasRelatedWork W274242853 @default.
• W3047316303 hasRelatedWork W2889396122 @default.
• W3047316303 hasRelatedWork W2904712747 @default.
• W3047316303 hasRelatedWork W2977626454 @default.
• W3047316303 hasRelatedWork W2992713492 @default.
• W3047316303 hasRelatedWork W3030321340 @default.
• W3047316303 hasRelatedWork W3180721253 @default.
• W3047316303 hasRelatedWork W3201178334 @default.
• W3047316303 hasRelatedWork W3213561768 @default.
• W3047316303 hasVolume "130" @default.
• W3047316303 isParatext "false" @default.
• W3047316303 isRetracted "false" @default.
• W3047316303 magId "3047316303" @default.
• W3047316303 workType "article" @default.